Indivior (INVVY) Rating Increased to Hold at Zacks Investment Research

Indivior (OTCMKTS:INVVY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Separately, ValuEngine upgraded Indivior from a “hold” rating to a “buy” rating in a report on Wednesday, November 29th.

Shares of Indivior (INVVY) opened at $27.90 on Wednesday. Indivior has a 1 year low of $17.50 and a 1 year high of $28.20. The company has a market cap of $4,023.12, a price-to-earnings ratio of 111.60, a P/E/G ratio of 5.37 and a beta of 1.13.

COPYRIGHT VIOLATION WARNING: “Indivior (INVVY) Rating Increased to Hold at Zacks Investment Research” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://transcriptdaily.com/2018/01/05/indivior-invvy-rating-increased-to-hold-at-zacks-investment-research.html.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply